Status:

COMPLETED

The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A

Lead Sponsor:

Ahvaz Jundishapur University of Medical Sciences

Conditions:

NAFLD

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

In this research, the investigators tested the effect of 12-week supplementation with soy isoflavones on non alcoholic fatty liver disease (NAFLD) management and the level of fibroblast growth factor-...

Detailed Description

Non-alcoholic fatty liver disease (NAFLD) accounts as a crucial health concern with a huge burden on health and economic systems. The aim of the present study was to investigate the effect of soy isof...

Eligibility Criteria

Inclusion

  • 18 years or older
  • without any history of allergy to soy or excessive consumption of soy products
  • without chronic diseases including renal, liver, heart, respiratory, cardiovascular, malignancies, auto immune disorders, cushing's syndrome, thyroid dysfunction, hepatitis, cirrhosis, biliary disorders, diabetes, gastrointestinal tract diseases affecting the gut absorption and psychiatric disorders considering as an obstacle for patients to prepare written informed consent;
  • hepatic steatosis grade 2 and higher with fibroscan confirmation (CAP \> 260 dB/m);
  • without history of excessive alcohol drink (≥10 g/day);
  • without history of drug consumption with approved positive effects on NAFLD treatment (i.e. metformin, vitamin E, ursodeoxycholic acid, phenytoin, tamoxifen, lithium, corticosteroids and methotrexate) in last three months;
  • without the history of bariatric surgery or following weight loss diets within 6 months;
  • without history of smoking;
  • not being a pregnant or lactating woman

Exclusion

  • consuming less than 90% of intended supplements.
  • unwillingness for study collaboration

Key Trial Info

Start Date :

September 6 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 11 2023

Estimated Enrollment :

46 Patients enrolled

Trial Details

Trial ID

NCT06101433

Start Date

September 6 2022

End Date

May 11 2023

Last Update

October 26 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Asal Neshatbini Tehrani

Ahvāz, Khuzestan, Iran, 78531-67465